



This is a repository copy of *Mollicutes antibiotic resistance profile and presence of genital abnormalities in couples attending an infertility clinic.*

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/143263/>

Version: Published Version

---

**Article:**

Maldonado-Arriaga, B., Escobar-Escamilla, N. [orcid.org/0000-0001-8929-476X](https://orcid.org/0000-0001-8929-476X), Pérez-Razo, J.C. et al. (9 more authors) (2020) *Mollicutes antibiotic resistance profile and presence of genital abnormalities in couples attending an infertility clinic*. *Journal of International Medical Research*, 48 (1). pp. 1-12. ISSN 0300-0605

<https://doi.org/10.1177/0300060519828945>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here:  
<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

# Mollicutes antibiotic resistance profile and presence of genital abnormalities in couples attending an infertility clinic

Journal of International Medical Research  
0(0) 1–12

© The Author(s) 2019

Article reuse guidelines:

[sagepub.com/journals-permissions](http://sagepub.com/journals-permissions)

DOI: 10.1177/0300060519828945

[journals.sagepub.com/home/imr](http://journals.sagepub.com/home/imr)

Brenda Maldonado-Arriaga<sup>1,5</sup>,  
Noé Escobar-Escamilla<sup>2</sup> ,  
Juan Carlos Pérez-Razo<sup>3</sup>,  
Sofía Lizeth Alcaráz-Estrada<sup>3</sup>,  
Ignacio Flores-Sánchez<sup>4</sup>,  
Daniel Moreno-García<sup>4</sup>,  
Rebeca Pérez-Cabeza de Vaca<sup>1</sup>,  
Paul Mondragón-Terán<sup>1</sup>, Jonathan Shaw<sup>6</sup>,  
Cecilia Hernandez-Cortez<sup>7</sup>,  
Graciela Castro-Escarpulli<sup>5</sup>  and  
Juan Antonio Suárez-Cuenca<sup>1</sup> 

<sup>1</sup>Laboratorio de Metabolismo Experimental e Investigación Clínica; División de Investigación Clínica y Coordinación de Investigación, C.M.N. “20 de Noviembre”, ISSSTE, San Lorenzo, Colonia del Valle Sur, Alcaldía Benito Juárez, C.P., Ciudad de México, México

<sup>2</sup>Transferencia de Métodos Moleculares, Departamento de Biología Molecular y Validación de Técnicas, Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Francisco de P. Miranda # 177, Colonia Unidad Lomas de Plateros, Alcaldía Álvaro Obregón. Ciudad de México C.P., México

<sup>3</sup>Unidad de Análisis y Referencia Viroológica, C.M.N. “20 de Noviembre”, ISSSTE, San Lorenzo, Colonia del Valle Sur, Alcaldía Benito Juárez, C.P., Ciudad de México, México

<sup>4</sup>Clínica de Infertilidad, Biología de la Reproducción C.M.N. “20 de Noviembre”, ISSSTE, Félix Cuevas, Colonia del Valle Sur, Alcaldía Benito Juárez, C.P., Ciudad de México, México

<sup>5</sup>Laboratorio de Investigación Clínica y Ambiental, Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional Prolongación de Carpio y Plan de Ayala S/N Colonia Plutarco Elías Calles, Alcaldía Miguel Hidalgo C.P., Ciudad de México

<sup>6</sup>Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, United Kingdom

<sup>7</sup>Laboratorio de Bioquímica Microbiana, Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional Prolongación de Carpio y Plan de Ayala S/N Colonia Plutarco Elías Calles, Alcaldía Miguel Hidalgo C.P., Ciudad de México

## Corresponding author:

Juan Antonio Suárez Cuenca, Laboratorio de Metabolismo Experimental e Investigación Clínica; Investigación Clínica, División de Investigación Biomédica, C.M.N. “20 de Noviembre”, ISSSTE, San Lorenzo No. 502, Colonia del Valle Sur, Alcaldía Benito Juárez, C.P. 03229, Ciudad de México, México.

Email: [suarej05@gmail.com](mailto:suarej05@gmail.com)



## Abstract

**Objective:** The present study aimed to identify Mollicutes infection in the reproductive system. We also examined the microbiological, biochemical, and antimicrobial profiles of Mollicutes infection, which are potentially associated with clinical reproductive abnormalities causing infertility in couples.

**Methods:** Thirty-seven couples who were attending an infertility clinic were enrolled. Detection of genital mycoplasmas was performed in cervicovaginal samples or male urethral swabs. Microbiological culture and biochemical and antimicrobial profiles were characterized using a Mycoplasma kit. The results were associated with reproductive abnormalities, as assessed by medical specialists from the infertility clinic.

**Results:** Up to 28.3% of all biological samples ( $n=74$ ) showed positive cultures. Bacterial isolates were *Ureaplasma urealyticum* (71.4%), *Mycoplasma hominis* (9.5%), or coinfections (19%). Most Mollicutes showed significant resistance to fluoroquinolones, macrolides, and tetracycline; and showed susceptibility to doxycycline, josamycin, and pristinamycin. The presence of resistant strains to any antibiotic was significantly associated with genital abnormalities ( $\chi^2$  test, relative risk = 11.38 [95% confidence interval: 5.8–22.9]), particularly in women. The highest statistical association was found for macrolide-resistant strains.

**Conclusion:** The microbiological antibiotic resistance profile is epidemiologically associated with abnormalities of the reproductive system in couples attending an infertility clinic.

## Keywords

Mollicutes, antimicrobial resistance profile, reproductive abnormalities, infertility, bacterial isolate, *Mycoplasma*

Date received: 16 November 2018; accepted: 15 January 2019

## Introduction

The World Health Organization, as well as the European Society of Human Reproduction and Embryology, define infertility as a disease of the reproductive system that leads to the inability to achieve a pregnancy after 12 months or longer with unprotected sex. Infertility is currently a problem of global distribution and increasing magnitude. An estimated 20% to 35% of all couples who wish to procreate have an infertility disorder.<sup>1</sup>

The main causes of infertility in couples include female endocrine disorders, ovulatory dysfunction, tubal and peritoneal diseases, and male endocrine and testicular disorders and seminal obstruction caused by sexually transmitted infections. Notably,

the male and female reproductive systems are suitable for growth of various pathogenic and non-pathogenic microorganisms.<sup>2</sup>

Genital mycoplasmas belong to an independent taxonomic class called Mollicutes and Mycoplasmataceae. This bacterial family includes *Mycoplasma* spp., *Mycoplasma hominis*, *Mycoplasma genitalium*, and *Ureaplasma urealyticum*. These species may cause oligo-symptomatic genital infections in women and men of reproductive age, such as urethritis, urinary tract infections, chorioamnionitis, pelvic inflammatory disease, and sperm cell disorders. Complications from these infections may lead to infertility.<sup>3,4</sup>

In Mexico, the National Health System has recognized the importance of infertility as a public health problem. However, only a

few studies have addressed infertility causes, and mainly evaluated non-infectious etiologies. Therefore, evaluating the potential participation of sexually transmitted infections is important because Mollicutes, such as *U. urealyticum* and *M. hominis*, have been identified in semen samples and endocervical exudates from Mexican couples with infertility.<sup>5</sup> Furthermore, *M. hominis* has been reported in 24.2% of infertile males with sperm abnormalities, whereas *U. urealyticum* has been reported in 86.8% of infertile females with tubular abnormalities.<sup>6</sup>

Antimicrobial therapy for Mollicutes genital mycoplasmas includes quinolones, tetracyclines, and macrolides as the drugs of choice. However, the indiscriminate use of antibiotics has promoted development of antibiotic-resistant strains.<sup>7</sup> Nonetheless, characterization of antibiotic resistance and its association with reproductive disorders in Mexican couples with infertility remain unclear. Therefore, this study aimed to identify Mollicutes infection in the reproductive system, as well as characterize its microbiological, biochemical, and antimicrobial profiles.

## Patients and methods

### Study population

In this cross-sectional study, 37 infertile couples were included from the Department of Assisted Reproduction National Medical Center “20 de Noviembre”, ISSSTE, Mexico City, Mexico between August 2015 and February 2016. Characteristics of the population, such as age, age at initiation of sexual activity, number of sexual partners, marital status, and infertility time, were collected from clinical records. Patients with anatomical alterations, genetic diseases, and endocrine disorders, and couples under antimicrobial treatment were excluded for at least 2 weeks before recruitment.

This study was designed and performed according to ethical guidelines of the 1975 Declaration of Helsinki. The study was approved by the Local Committees of Research, Ethics in Research, and Biosafety of the Centro Médico Nacional “20 de Noviembre”, ISSSTE, Mexico City (Protocol ID No. 033.2013). All participants provided written informed consent.

### Cervicovaginal samples

Samples were collected by specialized and experienced medical personnel according to the routine procedure in the Department of Reproductive Biology. For cervicovaginal exudate, the sample was taken by placing the patient in a gynecological position, and a sterile mirror was inserted into the vagina, which was lubricated with sterile water and heated to 37°C if necessary. The use of commercial lubricants or an antiseptic was avoided. Once the cervix was located, the mirror was fixed by opening the valves and a vaginal sac or cervix sample was taken, as appropriate. During routine sampling, two swabs were obtained for replicates of the samples. With the first swab, direct smears were stained with the Gram technique (to evaluate the Nugent criteria). The second swab was used for transport media R1 broth (Mycoplasma Gallery IST2) to detect the presence of mycoplasmas.<sup>8</sup>

### Urethral swabs

Patients were asked to retract the penis foreskin and keep it in this position throughout the procedure. The medical personnel used sterile cotton or gauze to clean the opening of the urethra at the tip of the penis. To collect the sample, a cotton applicator (cotton swab) was gently inserted approximately 2 cm into the urethra and turned. To obtain a good sample, the test was performed at least 2 hours

after urinating. The swab was placed in R1 broth (Mycoplasma Gallery IST2) to initiate isolation of mycoplasmas.

### Microbiological culture

The liquid media for *U. urealyticum* and *M. hominis* were inoculated from the transport medium R1 (Mycoplasma IST2 kit, Biomérieux, Marcy l'Etoile, France) A total of 150  $\mu\text{L}$  of the broth transport medium R1, containing the clinical sample, were inoculated. To perform phenotypic identification of *U. urealyticum*, urea broth was used, which contained medium base (pleuropneumonia-like organism broth), yeast extract, horse serum, and urea. To determine growth of this microorganism, phenol red was added to the culture medium because it turns from red to intense raspberry red in the presence of urease and ammonium production. Similarly, culture medium specific for *M. hominis* had arginine added. When metabolized, arginine produces an alkaline compound that turns phenol red to raspberry red. Culture media were incubated at 37°C until the phenol red indicator changed color. Solid cultures were performed using a rich medium supplemented with horse serum, yeast extract, and cysteine, and either urea substrates for *U. urealyticum* or arginine for *M. hominis* was added. Culture media were inoculated by adding three drops of 5  $\mu\text{L}$  each. The inoculated plates were incubated at 37°C in 5%  $\text{CO}_2$ , and were checked daily for colonial morphology of a "fried egg" for *M. hominis* or a "sea urchin" for *U. urealyticum*. A culture was considered negative if no colony growth was obtained after 15 days of incubation.<sup>9</sup> Strategies to minimize the chance of non-specific results included the following: 1) addition of polymyxin B, amphotericin B, and penicillin to cultures; 2) parallel assays using positive control of Mollicutes, and 3) all of the growth

obtained was further characterized by the IST2 gallery to evaluate specificity.

### Biochemical characterization

The Mycoplasma IST2 gallery was used according to the manufacturer's instructions as follows. A swab with the sample was placed in the transport medium R1 broth (3 mL). The broth was mixed with the lyophilisate R2 provided by the gallery, and this contained the substrates necessary for development of microorganisms. A volume of 50  $\mu\text{L}$  was distributed to each of the domes of the 22 tests that were divided into three sections. In the first section, phenotypic detection of *M. hominis* and *U. urealyticum* was performed. In the second section, microorganisms were quantified, with determination of whether the sample contained a concentration  $> 10^4$  change in color units (CCU)/sample. This indicated the importance of the presence of these microorganisms. In the last section, sensitivity tests were performed for different antimicrobials, and sensitivity was indicated by a change in color from yellow to red. Finally, after inoculation of each of the domes, two or three drops of sterile mineral oil were added. The gallery was incubated at 37°C and the results were recorded at 24 and 48 hours.<sup>10</sup>

### Clinical evaluation

Hysterosalpingography was performed in a radiology room. The patients lay on a table under an X-ray machine and placed their feet in stirrups. An instrument called a speculum was inserted into the vagina. After cleaning the cervix, the doctor passed a thin tube (catheter) through it. A dye (contrast medium) was passed through this tube, and it filled the uterus and fallopian tubes. X-rays were then taken. This contrast medium enabled these areas to be viewed on X-rays.<sup>11</sup> In spermatobioscopy,

the patient was asked for at least 3 days of sexual abstinence and not to perform intense physical exercise days before the analysis. The patient was required to masturbate in a clean room near the laboratory to process the sample and thus avoid thermal shock. A macroscopic study of the semen was performed to evaluate liquefaction, appearance, volume, pH, and viscosity. A microscopic study was performed later to evaluate sperm concentrations, presence of leukocytes, motility, vitality, and sperm morphology.<sup>12</sup> All of the study population was routinely searched for other genital pathogens, such as *Neisseria* and *Chlamydia*, with negative results.

### Statistical analysis

Data were analyzed using the Statistical Package for Social Sciences v.18.0. (SPSS Inc., Chicago, IL, USA) for Windows. A P value  $\leq 0.05$  (two-tailed) was considered to be statistically significant. Qualitative variables are described as mean and standard deviation, and were compared using the Student's t-test. The chi-square test was

calculated in the independence test of qualitative random variables.

## Results

The study population consisted of 74 patients (37 men and 37 women) who were recruited from the infertility clinic, aged 31 to 34 years old. Most of the patients had begun an active sexual life from the age of 18 years old. The most frequent number of sexual partners was more than three. There was a significant difference between sexual practices of men and women ( $p < 0.001$ ). A significantly higher proportion of men showed asymptomatic infections than did women ( $p < 0.001$ ). The most prevalent genitourinary symptom was secretion (women) and dysuria (men). For the time of infertility, most patients showed longer than 5 years. The detailed sociodemographic characteristics are shown in Table 1.

### Characterization of specimens

Seventy-four samples of cervical and urethral exudates were collected, and the

**Table 1.** Demographic and clinical characteristics of couples with infertility.

|                                    | Men<br>(n = 37) | Women<br>(n = 37) | p value |
|------------------------------------|-----------------|-------------------|---------|
| Age (years)                        | 34.7 $\pm$ 0.21 | 31.5 $\pm$ 1.4    | N.S.    |
| Start of sexual life < 18 years    | 12 (32.4)       | 5 (13.5)          | 0.04    |
| Number of previous sexual partners |                 |                   |         |
| 1–2                                | 5 (13.5)        | 18 (48.6)         |         |
| 3–4                                | 17 (45.9)       | 14 (37.8)         | 0.001   |
| $\geq 5$                           | 16 (43.2)       | 5 (13.5)          |         |
| Genitourinary symptoms             |                 |                   |         |
| Symptomatic*                       | 11 (29.7)       | 28 (75.7)         | <0.001  |
| Asymptomatic                       | 26 (70.3)       | 9 (24.3)          |         |
| Years of infertility <sup>#</sup>  |                 |                   |         |
| <5 years                           |                 | 29 (78.3)         | <0.001  |
| $\geq 5$ years                     |                 | 8 (21.6)          |         |

Quantitative data are shown as mean  $\pm$  standard deviation. Qualitative data are shown as number (%). <sup>#</sup>Determined by the number of couples. Statistical analysis was performed with Fisher's test. \*Symptomatic was considered as any combination of secretion, itching, and/or burning when urinating.

analysis included two methods of characterization: microbiological (culture conditions, Nugent criteria occurred in < 10%, and related to *M. hominis*) and biochemical (by the Mycoplasma IST2 kit) (Figure 1). By using these approaches, we observed a 100% diagnostic agreement between both methods, where genital mycoplasmas were isolated from 21 (28.3%) samples, either as a single microorganism or as a coinfection with both types of genital mycoplasmas. Notably, *U. urealyticum* was found in 15 of 21 samples as a single infective bacterium. *U. urealyticum* was found as a coinfection with *M. hominis* in four samples. *M. hominis* was found in two samples.

The presence of genital mycoplasmas, as a shared infection between couples, was observed in 76% of patients. Notably, genital mycoplasmas showed a threshold concentration of  $\geq 10^4$  CCU, which indicated active infection in all of the patients.

Additionally, biochemical characterization was performed to detect antibiotic resistance profiles of the microorganisms. These microorganisms included fluoroquinolone-resistant

strains of *U. urealyticum*, particularly to ciprofloxacin (86.6%) and ofloxacin (80%), whereas they were highly sensitive to doxycycline, josamycin, and pristinamycin. *M. hominis* strains were completely resistant to macrolides (erythromycin, tetracycline, clarithromycin, and azithromycin). However, fluoroquinolone resistance was found in 50% of cases and the strains were highly susceptible to doxycycline, josamycin, and pristinamycin. When *U. urealyticum* and *M. hominis* were found as coinfection, resistance to most antibiotics was observed, mainly to fluoroquinolones and macrolides (Table 2).

#### Association of antibiotic resistance in Mollicutes with the clinical condition of patients with infertility

Clinical conditions that are associated with infertility in males, such as asthenospermia and azoospermia, showed a higher prevalence in the population who was infected with genital mycoplasmas (both  $p < 0.001$ ). However, those without



**Figure 1.** Characterization of clinical specimens. Left panels: bacteria growing in pleuropneumonia-like organism medium. (a) *Mycoplasma hominis* shows a characteristic “fried egg” shape. (b) *Ureaplasma urealyticum* shows a “sea urchin” shape. Right panels: Biochemical characterization using the Mycoplasma IST2 kit. The first three domes on the left are intended for identification purposes. The next two domes are intended for quantification purposes. The last nine domes are intended for characterization of antibiotic resistance, according to color development: yellow (susceptible) or red (resistant).

**Table 2.** *Ureaplasma urealyticum* and *Mycoplasma hominis* antimicrobial profile of all samples.

| Antimicrobial  | <i>Ureaplasma urealyticum</i><br>(n = 15) |           | <i>Mycoplasma hominis</i><br>(n = 2) |         | <i>Ureaplasma urealyticum</i><br>+ <i>Mycoplasma hominis</i><br>(n = 4) |         |
|----------------|---|-----------|--------------------------------------|---------|---|---------|
|                | S   | R         | S                                    | R       | S   | R       |
| Doxycycline    | 15 (100)                                  | 0 (0)     | 2 (100)                              | 0 (0)   | 4 (100)   | 0 (0)   |
| Tetracycline   | 3 (20)                                    | 12 (80)   | 0 (0)                                | 2 (100) | 2 (50)  | 2 (50)  |
| Josamycin      | 15 (100)                                  | 0 (0)     | 2 (100)                              | 0 (0)   | 2 (50)  | 2 (50)  |
| Erythromycin   | 13 (86.6)                                 | 2 (13.3)  | 0 (0)                                | 2 (100) | 2 (50)  | 2 (50)  |
| Azithromycin   | 13 (86.6)                                 | 2 (13.3)  | 0 (0)                                | 2 (100) | 0 (0)   | 4 (100) |
| Clarithromycin | 14 (93.3)                                 | 1 (6.66)  | 0 (0)                                | 2 (100) | 0 (0)   | 4 (100) |
| Ofloxacin      | 3 (20.0)                                  | 12 (80.0) | 0 (0)                                | 2 (100) | 0 (0)   | 4 (100) |
| Ciprofloxacin  | 2 (13.3)                                  | 13 (86.6) | 0 (0)                                | 2 (100) | 0 (0)   | 4 (100) |
| Pristinamycin  | 15 (100)                                  | 0 (0)     | 2 (100)                              | 0 (0)   | 0 (0)   | 0 (0)   |

Qualitative data are shown as number (%). Samples included were individual and mixed cervicovaginal and urethral samples.

**Table 3.** Clinical condition associated with genital mycoplasma infection (n = 37).

|  | AS*      | AZ*      | OL       | OL-I     | TO <sup>#</sup> | PRM <sup>#</sup> | EP <sup>#</sup> | NCE     | C       |
|--|----------|----------|----------|----------|-----------------|------------------|-----------------|---------|---------|
| <i>M. hominis</i>                              | 0 (0)    | 0 (0)    | 0 (0)    | 0 (0)    | 2 (16.6)        | 0 (0)            | 0 (0)           | 0 (0)   | 0 (0)   |
| <i>U. urealyticum</i>                          | 5 (55.5) | 2 (22.2) | 0 (0)    | 0 (0)    | 8 (66.6)        | 8 (66.6)         | 5 (41.6)        | 1 (8.3) | 1 (8.3) |
| <i>M. hominis</i> and<br><i>U. urealyticum</i> | 0 (0)    | 0 (0)    | 1 (11.1) | 1 (11.1) | 2 (16.6)        | 0 (0)            | 0 (0)           | 0 (0)   | 0 (0)   |

Data are shown as number (%). The symbols indicate conditions associated with infection of genital mycoplasmas in men (\*) and women (<sup>#</sup>),  $p < 0.001$ . AS, asthenospermia; AZ, azoospermia; OL, oligoasthenozoospermia; OL-I, oligoasthenoteratozoospermia; TO, tubular obstruction; EP, ectopic pregnancy; PRM, premature rupture of the membranes; NCE, nonspecific chronic endocervicitis; C, cervicitis; *U.*, *Ureaplasma*; *M.*, *Mycoplasma*.

genital mycoplasma infection did not present with any abnormalities. In women, unilateral and bilateral tubular obstruction, premature rupture of the fetal membranes, and ectopic pregnancies occurred significantly more frequently in patients who were positive for genital mycoplasma infection than in those who were not positive for genital mycoplasma infection (all  $p < 0.001$ ) (Table 3).

Furthermore, a higher prevalence and significant association (chi-square test,  $p < 0.0001$ ) was found between microorganisms that were resistant to any antibiotic and the presence of any genital abnormality

(relative risk [RR] = 11.38, 95% confidence interval [CI]: 5.8–22.9,  $p < 0.0001$ , Appendix 1). This finding was also observed for most of the antibiotic groups tested, including tetracyclines (RR = 6.5, 95% CI: 2.1–19.5,  $p < 0.0001$ ), macrolides (RR = 37.7, 95% CI: 5.25–271,  $p < 0.0001$ ), quinolones (RR = 1.1, 95% CI: 0.81–1.6,  $p = 0.25$ ), and pristinamycin (RR = 9, 95% CI: 0.85–94.9,  $p = 0.19$ ).

## Discussion

The main finding of the present study was the higher prevalence of Mollicutes that was

resistant to any antibiotic within the group of patients with genital abnormalities among couples who were attending an infertility clinic. The study population was characterized by couples aged 31 to 34 years. There was a significant difference between sexual practices of men and women. More than two thirds of men showed asymptomatic infections and approximately three quarters of the women were symptomatic. The higher prevalence of infection in women with identifiable clinical conditions related to infertility is consistent with previous reports.<sup>13,14</sup> This finding supports the epidemiological association between Mollicutes infection and infertility in women.

Similar to previous studies, we observed that *U. urealyticum* was the most prevalent (71%) species that was isolated in samples of the cervix and urethra from the studied couples. The reported prevalence of *U. urealyticum* cervical infection in similar populations varies from 50% to 80%,<sup>15</sup> whereas its prevalence may reach up to 90% in women who are sexually active. *M. hominis* infection was the next most prevalent infection in our study. The presence of *M. hominis* is relevant because it contributes to polybacterial infection known as “bacterial vaginosis”. This condition is considered a dysbiosis related to the absence of *Lactobacilli* and an increase in vaginal pH that favors further infections. In fact, synergism between *M. hominis* and other microorganisms causing bacterial vaginosis has been suggested. Similarly, studies in the Italian population have reported a higher prevalence of *U. urealyticum* and *M. hominis*, and a possible association of *M. hominis* with bacterial vaginosis.<sup>16-20</sup>

In some patients, we observed coinfection of *Ureaplasma* spp. with *M. hominis*, which is expected. *Ureaplasma* spp. and *M. hominis* may become opportunistic agents under immunocompromising situations, and rapidly increase their bacterial

load (determined by quantitative PCR and/or microbiological culture). This is considered a useful marker of clinically significant infection.<sup>21</sup> Furthermore, coinfection with other microorganisms is considered important information because of potential interactions with Mollicutes. An example of this situation is that coinfection of human papilloma virus and Mollicutes has been suggested to accelerate tissue damage, leading to organ dysfunction.

*M. hominis* and *Ureaplasma* spp. have been implicated in a wide variety of infections that may lead to infertility. Female chronic genital infection might induce adhesions to the inside and outside of fallopian tubes. This results in obstruction of the fallopian tube and is an obstacle for union of the sperm and egg. Infection is also related to ectopic pregnancies and premature rupture of the membranes, leading to a lower possibility of pregnancy. This is consistent with our finding of a higher prevalence of genital Mollicutes in women who had any reproductive abnormality. Similarly, a Danish study showed a significant correlation between the presence of *M. hominis* and *U. urealyticum* with tubal abnormalities in a population of 304 infertile women.<sup>22</sup> Genito-urinary infections, such as urethritis, prostatitis, and other inflammatory processes, are also related to 15% of male infertility.<sup>23</sup> Mollicutes is particularly associated with sperm abnormalities, such as aberrant motility, deficient mitochondrial function, and loss of DNA integrity.<sup>24-27</sup> Increased formation of hydrogen peroxide and reactive oxygen species might induce peroxidation of sperm lipids, which causes an internal alteration that makes them incapable of moving.<sup>28</sup> *U. urealyticum* has been described as the most frequent species related to male reproductive system abnormalities.<sup>29-31</sup> Consistently, *U. urealyticum* is the most frequent species in men with infertility; although most of our male affected population did not show any genital infections.

This finding is in contrast to a previous report, which showed that the presence of *U. urealyticum* and *M. hominis* was related to impaired density of semen, and abnormal sperm vitality and motility in infertile men.<sup>8,32</sup> Such differences in observations may be explained by methodological variations in the tests used to evaluate sperm.

With regard to the antibiotic profile, *U. urealyticum* isolates showed a high rate of fluoroquinolone resistance; while *M. hominis* showed resistance to macrolides. These profiles are consistent with previous reports<sup>9–33</sup> and may be related to the widespread use of fluoroquinolones within the Mexican population, especially as therapy for urinary infections.<sup>33</sup> Moreover, Mexican official therapeutic guidelines<sup>32</sup> recommend that symptomatic sexually transmitted infections (where *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *M. hominis*, *U. urealyticum*, and other facultative anaerobic bacteria have been identified by culture media or quantitative PCR) be treated with fluoroquinolones or clindamycin for ambulatory patients, or cephalosporin and doxycycline in case of in-hospital treatment. This may affect prognosis of the ambulatory population because of the antibiotic resistance profile, which may lead to additional resistance to antimicrobials, therapeutic failure, and chronic infection with potential complications. Interestingly, *U. urealyticum* and *M. hominis* isolates were highly sensitive to agents, such as doxycycline, josamycin, and pristinamycin, which is consistent with the pattern of antibiotic resistance found in other populations.<sup>11,12,18,34</sup> Generally, our findings support the benefit of routine isolation of microorganisms as part of a comprehensive evaluation and therapy during infertility studies.

Interestingly, we found that the presence of antibiotic-resistant strains of genital Mollicutes were associated with reproductive abnormalities in the study population, particularly in women. Previous reports

have described the distribution of antibiotic-resistant strains of genital Mollicutes in populations with infertility.<sup>35–38</sup> However, to the best of our knowledge, this is the first study to evaluate the role of bacterial antibiotic resistance in clinical reproductive abnormalities in couples attending an infertility clinic. Although the precise mechanism remains unclear, we believe that a relation of antibiotic-resistant strains with reproductive abnormalities and infertility is feasible. This is because novel mechanisms of antibiotic-resistant bacteria suggest induction of microbiota dysbiosis, which facilitates bacterial migration and translocation, and is potentially associated with higher damage in reproductive organs.<sup>39,40</sup>

In conclusion, the microbiological antibiotic resistance profile is associated with abnormalities of the reproductive system in Mexican couples attending an infertility clinic.

### Acknowledgments

We would like to thank Sofia Mulia for kindly correcting the style of the manuscript.

### Declaration of conflicting interest

The authors declare that there is no conflict of interest.

### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the E-015 institutional program and Secretaría de Investigación y Posgrado del Instituto Politécnico Nacional (SIP 20171099 and 20180060) (IPN). Brenda Maldonado Arriaga had a scholarship from CONACyT. Graciela Castro Escarpulli received support from Estímulos al Desempeño en Investigación, Comisión y Fomento de Actividades Académicas (Instituto Politécnico Nacional), and Sistema Nacional de Investigadores (SNI, CONACyT).

**ORCID iD**

Noé Escobar-Escamilla  <http://orcid.org/0000-0001-8929-476X>

Graciela Castro-Escarpulli  <http://orcid.org/0000-0002-7496-8247>

Juan Antonio Suárez-Cuenca  <http://orcid.org/0000-0002-2098-5658>

**References**

1. Matorras R. *La infertilidad en España, situación actual y perspectivas*. 5th ed. Madrid, 2011, p.19.
2. Vite J, Ortiz D and Hernández I. *Análisis epidemiológico de la Infertilidad en una población mexicana*. México: Ginecología Obstetra, 2005, p.360.
3. Valentine-King MA and Brown MB. Antibacterial resistance in *ureaplasma* species and *mycoplasma hominis* isolates from urine cultures in college-aged females. *Antimicrob Agents Chemother* 2017; 61: 1104.
4. Ausinan V and Moreno G. *Tratado SEIMC de Enfermedades Infecciosas y Microbiología Clínica*. 1st ed. Madrid, 2006, pp.557–564.
5. López-Avila K, Zavala-Castro J, Arias-León J, et al. Infertilidad humana causada por *Mycoplasma* spp. *Revista Biomédica* 2014; 25: 74–90.
6. Hernández-Marín I, Aragón-López C, Aldama-González PL, et al. Prevalence of infections (*chlamydia*, *ureaplasma* and *mycoplasma*) in patients with altered tuboperitoneal factor. *Ginecol Obstet Mex* 2016; 84: 14–18 [in Spanish, English Abstract].
7. Farinati AE. *Mycoplasma genitalium* ¿Inocente o culpable? *La Gaceta de Infectología y Microbiología Clínica* 2009; 3: 6–11.
8. D'Inzeo T, De Angelis G, Fiori B, et al. Comparison of mycoplasma IES, mycofast revolution and mycoplasma IST2 to detect genital mycoplasmas in clinical samples. *J Infect Dev Ctries* 2017; 11: 98–101.
9. Degrange H, Renaudin A and Charron CB. Tetracycline resistance in *Ureaplasma* spp. and *Mycoplasma hominis*: prevalence in Bordeaux, France, from 1999 to 2002 and description of two *tet(M)*-positive isolates of *M. hominis* susceptible to tetracyclines. *Antimicrob Agents Chemother* 2008; 52: 742–744.
10. Mardassi BB, Aissani N, Moalla I, et al. Evidence for the predominance of a single *tet(M)* gene sequence type in tetracycline-resistant *Ureaplasma parvum* and *Mycoplasma hominis* isolates from Tunisian patients. *J Med Microbiol* 2012; 61(Pt 9): 1254–1261.
11. Mena LA, Mroczkowski TF, Nsuami M and Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of *Mycoplasma genitalium*-positive urethritis in men. *Clin Infect Dis* 2009; 48: 1649–1654. doi: 10.1086/599033.
12. Taylor-Robinson D. Diagnosis and antimicrobial treatment of *Mycoplasma genitalium* infection: sobering thoughts. *Expert Rev Anti Infect Ther* 2014; 12: 715–722.
13. Alfarraj DA and Somily AM. Isolation of mycoplasma genitalium from endocervical swabs of infertile women. *Saudi Med J* 2017; 38: 549–552.
14. Tsevat DG, Wiesenfeld HC, Parks C, et al. Sexually transmitted diseases and infertility. *Am J Obstet Gynecol* 2017; 216: 1–9.
15. Mihai M, Valentin N, Bogdan D, et al. Antibiotic susceptibility profiles of mycoplasma hominis and ureaplasma urealyticum isolated during a population-based study concerning women infertility in Northeast Romania. *Braz J Microbiol* 2011; 42: 256–260.
16. Muñoz-Becerril B, Hernández-García JA, Castro-Escarpulli, et al. Detección y resistencia antimicrobiana en muestras de exudado vaginal de *Mycoplasma hominis* y *Ureaplasma urealyticum*. *Noticonaquic* 2010; 49: 26–39.
17. Foschi C, Salvo M, D'Antuono A, et al. Distribution of genital *Mollicutes* in the vaginal ecosystem of women with different clinical conditions. *New Microbiol* 2018; 41: 225–229.
18. Foschi C, Salvo M, Galli S, et al. Prevalence and antimicrobial resistance of genital *Mollicutes* in Italy over a two-year period. *New Microbiol* 2018; 41: 153–158.

19. Fettweis JM, Serrano MG, Huang B, et al. An emerging *mycoplasma* associated with trichomoniasis, vaginal infection and disease. *PLoS One* 2014; 9: e110943.
20. Seifoleslami M, Safari A and Khayyat Khameneie M. Prevalence of ureaplasma urealyticum and mycoplasma hominis in high vaginal swab samples of infertile females. *Iran Red Crescent Med J* 2015; 17: e16823.
21. Jensen JS, Björnelius E, Dohn B, et al. Comparison of first void urine and urogenital swab specimens for detection of *Mycoplasma genitalium* and *Chlamydia trachomatis* by polymerase chain reaction in patients attending a sexually transmitted disease clinic. *Sex Transm Dis* 2004; 31: 499–507.
22. Andreeva and Dimitrov. The microorganisms associated with bacterial vaginosis as a cause of tubal sterility. *Akush Ginekol (Sofia)* 2002; 41: 35–39 [in Bulgarian, English Abstract].
23. Wang CL, Liang JQ, Wu JQ, et al. Do *Ureaplasma urealyticum* infections in the genital tract affect semen quality? *Asian J Androl* 2006; 8: 562–568.
24. Haggerty CL, Totten PA, Tang G, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. *Sex Transm Infect* 2016; 92: 441–446.
25. Gdoura R, Kchaou W, Chaari, C, et al. *Ureaplasma urealyticum*, *Ureaplasma parvum*, *Mycoplasma hominis* and *Mycoplasma genitalium* infections and semen quality of infertile men. *BMC Infect Dis* 2007; 7: 129.
26. Ramazanzadeh R, Khodabandehloo M, Farhadifar F, et al. Case–control study on the relationship between *mycoplasma genitalium* infection in women with normal pregnancy and spontaneous abortion using polymerase chain reaction. *Osong Public Health Res Perspect* 2016; 7: 334–338.
27. Solomon M and Henkel R. Semen culture and the assessment of genitourinary tract infections. *Indian J Urol* 2017; 33: 188–193.
28. Purvis K and Christiansen E. Infection in the male reproductive tract and the impact, diagnosis and treatment in relation to male infertility. *Int J Androl* 1993; 16: 1–13.
29. Sanocka-Maciejewska D, Ciupinska M and Kurpisz M. Bacterial infection and semen quality. *J Reprod Immunol* 2005; 67: 51–56.
30. Ruan Z, Yang T, Shi X, et al. Clonality and distribution of clinical *Ureaplasma* isolates recovered from male patients and infertile couples in China. *PLoS One* 2017; 12: e0183947.
31. Dhawan B, Malhotra N, Sreenivas V, et al. *Ureaplasma* serovars & their antimicrobial susceptibility in patients of infertility and genital tract infections. *Indian J Med Res* 2012; 6: 991–996.
32. Waites KB, Duffy LB, Bébéar CM, et al. Standardized methods and quality control limits for agar and broth microdilution susceptibility testing of *Mycoplasma pneumoniae*, *Mycoplasma hominis*, and *Ureaplasma urealyticum*. *J Clin Microbiol* 2012; 50: 3542–3547.
33. Campos GB, Lobão TN, Selis N, et al. Prevalence of *Mycoplasma genitalium* and *Mycoplasma hominis* in urogenital tract of Brazilian women. *BMC Infect Dis* 2015; 15: 60.
34. NOM-039-SSA2:2002. Para la prevención y control de las infecciones de transmisión sexual.
35. Anagrius C, Lore B and Jensen JS. Treatment of *Mycoplasma genitalium*. Observations from a Swedish STD clinic. *PLoS One* 2013; 8: e61481.
36. Pond MJ, Nori AV, Witney AA, et al. High prevalence of antibiotic-resistant *Mycoplasma genitalium* in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. *Clin Infect Dis* 2014; 58: 631–637.
37. Yu LC, Shih YA, Wu LL, et al. Enteric dysbiosis promotes antibiotic-resistant bacterial infection: systemic dissemination of resistant and commensal bacteria through epithelial transcytosis. *Am J Physiol Gastrointest Liver Physiol* 2014; 307: G824–G835.
38. Deguchi T, Yoshida T, Yokoi S, et al. Longitudinal quantitative detection by

- real-time PCR of *Mycoplasma genitalium* in first-pass urine of men with recurrent non-gonococcal urethritis. *J Clin Microbiol* 2002; 40: 3854–3856.
39. Yoshida T, Deguchi T, Ito M, et al. Quantitative detection of *Mycoplasma genitalium* from first-pass urine of men with urethritis and asymptomatic men by real-time PCR. *J Clin Microbiol* 2002; 40: 1451–1455.
40. Jamalizadeh Bahaabadi S, Mohseni Moghadam N, Kheirkhah B, et al. Isolation and molecular identification of *Mycoplasma hominis* in infertile female and male reproductive system. *Nephrourology Mon* 2014; 6: e22390.

### Appendix I. Antimicrobial resistance profile and genital abnormalities.

|                | With genital abnormalities |           |                   |         |  |         | Without genital abnormalities |          |                   |         |  |        |
|----------------|----------------------------|-----------|-------------------|---------|--|---------|-------------------------------|----------|-------------------|---------|--|--------|
|                | <i>U. urealyticum</i>      |           | <i>M. hominis</i> |         | <i>U. urealyticum</i><br>+ <i>M. hominis</i> |         | <i>U. urealyticum</i>         |          | <i>M. hominis</i> |         | <i>U. urealyticum</i><br>+ <i>M. hominis</i> |        |
|                | S                          | R         | S                 | R       | S  | R       | S                             | R        | S                 | R       | S  | R      |
| Doxycycline    | –                          | –         | –                 | –       | –  | –       | 15 (100)                      | 0 (0)    | 2 (100)           | 0 (0)   | 4 (100)                                      | 0 (0)  |
| Tetracycline   | 3 (20)                     | 12 (80)   | –                 | –       | –  | –       | –                             | –        | 0 (0)             | 2 (100) | 2 (50)                                       | 2 (50) |
| Josamycin      | –                          | –         | –                 | –       | –  | –       | 15 (100)                      | 0 (0)    | 2 (100)           | 0 (0)   | 2 (50)                                       | 2 (50) |
| Erythromycin   | –                          | –         | 0 (0)             | 2 (100) | –  | –       | 13 (86.6)                     | 2 (13.3) | –                 | –       | 2 (50)                                       | 2 (50) |
| Azithromycin   | –                          | –         | 0 (0)             | 2 (100) | 0 (0)  | 4 (100) | 13 (86.6)                     | 2 (13.3) | –                 | –       | –  | –      |
| Clarithromycin | –                          | –         | 0 (0)             | 2 (100) | 0 (0)  | 4 (100) | 14 (93.3)                     | 1 (6.66) | –                 | –       | –  | –      |
| Ofloxacin      | 3 (20.0)                   | 12 (80.0) | 0 (0)             | 2 (100) | 0 (0)  | 4 (100) | –                             | –        | –                 | –       | –  | –      |
| Ciprofloxacin  | 2 (13.3)                   | 13 (86.6) | 0 (0)             | 2 (100) | 0 (0)  | 4 (100) | –                             | –        | –                 | –       | –  | –      |
| Pristinamycin  | –                          | –         | –                 | –       | –  | –       | 15 (100)                      | 0 (0)    | 2 (100)           | 0 (0)   | 0 (0)  | 0 (0)  |

Qualitative data are shown as number (%). Samples included were individual and mixed cervicovaginal and urethral samples. *U.*, *Ureaplasma*; *M.*, *Mycoplasma*; S, sensitive; R, resistant.